E11.351

Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema

This specific ICD-10 code, E11.351, identifies Type 2 Diabetes Mellitus with the advanced ocular complication of proliferative diabetic retinopathy (PDR) that is concurrently presenting with macular edema. Type 2 diabetes is a chronic metabolic disorder characterized by sustained elevated blood glucose levels, primarily stemming from insulin resistance and/or inadequate insulin secretion. Prolonged hyperglycemia, combined with other systemic factors like hypertension and dyslipidemia, progressively damages the microvasculature throughout the body, with the retinal capillaries being particularly vulnerable. Diabetic retinopathy evolves through stages, from non-proliferative (NPDR) to its most severe form, PDR. PDR is characterized by widespread retinal ischemia, which triggers the release of angiogenic factors, most notably vascular endothelial growth factor (VEGF). This leads to the pathological growth of new, fragile blood vessels (neovascularization) on the surface of the retina or optic disc. These new vessels are inherently weak, prone to leakage and hemorrhage, which can result in vitreous hemorrhage, causing sudden, significant vision loss. Furthermore, these neovascular membranes can proliferate with fibrous components, contracting and pulling on the retina, potentially leading to tractional retinal detachment, a sight-threatening condition. Concurrently, macular edema signifies the accumulation of fluid within the macula, the central part of the retina responsible for high-acuity central vision. This leakage occurs due to increased permeability of damaged capillaries in the macular region. The presence of macular edema, alongside PDR, particularly when PDR is actively causing significant retinal damage, represents a critical stage of diabetic eye disease with a high risk of permanent vision impairment or blindness if not promptly and aggressively managed. Treatment strategies are multifaceted and typically involve stringent control of blood glucose, blood pressure, and lipids, alongside targeted ophthalmic interventions. These often include intravitreal injections of anti-VEGF agents to suppress neovascularization and reduce macular edema, laser photocoagulation (panretinal photocoagulation for PDR, and focal/grid laser for macular edema), and vitrectomy for complications such as non-clearing vitreous hemorrhage or tractional retinal detachment. Regular comprehensive dilated eye exams are crucial for early detection and timely intervention, preventing irreversible vision loss associated with this severe complication of diabetes.

Clinical Symptoms

  • Blurred or distorted central vision (due to macular edema)
  • Floaters or dark spots in the visual field (due to vitreous hemorrhage from new vessels)
  • Flashes of light
  • Sudden, severe vision loss (due to vitreous hemorrhage or retinal detachment)
  • Difficulty with night vision
  • Reduced color vision
  • Blind spots

Common Causes

  • Long-standing and poorly controlled Type 2 diabetes mellitus
  • Chronic hyperglycemia leading to microvascular damage
  • High blood pressure (hypertension)
  • High cholesterol (dyslipidemia)
  • Smoking
  • Genetic predisposition
  • Kidney disease

Documentation & Coding Tips

Explicitly document the type of diabetes, the specific ocular complications (proliferative diabetic retinopathy and macular edema), and their direct causal link. Always include objective findings and assessment of severity.

Example: Patient is a 68-year-old male with Type 2 Diabetes Mellitus (E11.9, HCC 19) exhibiting persistent blurry vision, worse in the left eye. Funduscopic exam reveals bilateral proliferative diabetic retinopathy (PDR) with active neovascularization, more prominent in the left eye. Optical Coherence Tomography (OCT) confirms significant macular edema in the left eye (central subfield thickness 450 microns), with mild macular thickening in the right eye (300 microns). Visual acuity is 20/70 OS and 20/40 OD. Assessment: Type 2 Diabetes Mellitus with Proliferative Diabetic Retinopathy with Macular Edema, left eye (E11.351). The patient is actively managed with intravitreal anti-VEGF injections for the left eye, with a scheduled injection next week. Continued close monitoring of both eyes for disease progression and response to therapy. This condition significantly impacts the patient's functional status and requires ongoing specialized care.

Billing Focus: Specificity of Type 2 DM, 'proliferative' stage of retinopathy, explicit mention of 'macular edema', and laterality (though E11.351 is bilateral in description, clinical note should specify worse eye if applicable). Documentation of active management (e.g., anti-VEGF, laser) supports medical necessity for related CPT codes.

Provide detailed objective clinical findings for both proliferative diabetic retinopathy and macular edema, including visual acuity, imaging results (OCT, fluorescein angiography), and any treatment interventions (e.g., anti-VEGF injections, laser photocoagulation).

Example: 62-year-old female with long-standing Type 2 Diabetes Mellitus (E11.9, HCC 19) presents for follow-up of diabetic retinopathy. Current visual acuity: 20/50 OD, 20/80 OS. Previous intravitreal aflibercept injection OS was 4 weeks ago. OCT shows persistent intraretinal and subretinal fluid with foveal involvement in the left eye (central subfield thickness 420 microns OS), confirming active macular edema. OD shows resolving fluid (280 microns) with mild non-proliferative changes. Fundus examination reveals areas of neovascularization elsewhere (NVE) on disc and along superior arcade OS, indicating active proliferative diabetic retinopathy. No new vitreous hemorrhage. Assessment: Type 2 Diabetes Mellitus with Proliferative Diabetic Retinopathy with Macular Edema, bilateral, worse left eye (E11.351). Plan: Repeat intravitreal aflibercept injection OS today. Continue close monitoring of OD. Reinforce strict glycemic control.

Billing Focus: Inclusion of objective measures (visual acuity, OCT findings with specific measurements, funduscopic details like NVE) justifies the diagnosis and medical necessity for diagnostic tests (e.g., OCT, angiography) and therapeutic procedures (e.g., injections). Specificity regarding laterality (if noted clinically) enhances clarity for claims.

Relevant CPT Codes

Related Diagnoses

Hierarchy